TOPIC

/ company

Value Partners

Value Partners is one of Asia’s largest asset management firms, with US$8.6 billion in assets under management as of June this year. In November 2007, it became the first asset management firm to list on the Hong Kong Stock Exchange.

Chairman / President

Dato’ Seri Cheah Cheng Hye

CEO / Managing Director

Louis So

CFO / Finance Director

Nikita Ng

Industry

Asset management

Website

valuepartners-group.com

Headquarters address

43/F, The Center, 99 Queen's Road Central, Hong Kong

Stock Code

SEHK:0806

Year founded

1993

Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So

Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

14 Aug 2026 - 6:00PMvideocam

China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

8 Aug 2026 - 6:34PM

Commodities

China’s resources deals turn gold mines into – gold mines

18 Jul 2026 - 4:21AMvideocam

China stock market

China’s divergent stock market displays a microcosm of the nation’s economy

The stock market catalogues China’s uneven growth, as manufacturing expands and consumption falls.

6 Jul 2026 - 8:30AM

A large screen shows the latest stock market data in Shanghai, China, on June 15. Photo: EPA

Hong Kong stock market

Is Hong Kong losing its tech edge to the mainland’s AI boom?

Chinese investors are shifting from Hong Kong to mainland stocks, driven by AI opportunities and better returns.

5 Jun 2026 - 7:00AM

China stock market

China equities set for boost as Trump-Xi meeting raises hopes of thaw

Investors are betting a Trump-Xi summit will ease tensions, helping Chinese equities close their long-standing valuation gap.

27 Apr 2026 - 5:30PM

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

18 Apr 2026 - 11:05AM

China stock market

Trump’s Fed pick Warsh stokes uncertainty as investors weigh his policy shifts

US Treasuries have been falling recently, partially reflecting investor concerns that Warsh’s succession will slow rate reductions.

8 Mar 2026 - 9:30AM

Hong Kong

Hong Kong’s new cash-for-residency scheme draws US$12 billion in first 2 years

Number of applicants surges in second year, with most of the deployed capital going into authorised funds, equities and debt securities.

2 Mar 2026 - 2:44PM

Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

21 Jan 2026 - 7:43AM

Global drug companies no longer view Chinese firms as contract manufacturers, but as development partners, an analyst says. Photo: Shutterstock

Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

20 Jan 2026 - 11:16AM

Leung Chuen-yan, partner for healthcare investment at Value Partners Group. Photo: Edmond So

Banking & finance

Hong Kong taps Value Partners, 9 others to manage US$385 million residency fund

Government investment arm HKIC also names Primavera among managers of CIES IP, which focuses on Hong Kong’s long-term development.

2 Dec 2025 - 3:36PM

Banking & finance

Adams Street joins wave of investment firms opening in Hong Kong

‘We want to be closer to both our investors and the investment opportunities that are presenting themselves here,’ managing partner says.

17 Nov 2025 - 8:30AM

International Property

JD’s property arm joins 2 firms in US$1 billion Singapore Reit: sources

JD Property is setting up the US$1 billion Reit with Swiss investment firm Partners Group and Hillhouse’s EZA Hill Property, sources said.

28 Aug 2025 - 10:13AM

A view of the central business district skyline in Singapore on May 27, 2025. Photo: Reuters

Hong Kong economy

Efforts needed to combat view ‘Hong Kong equals mainland China’: business leaders

Panellists at South China Morning Post’s China Conference 2025 also say city maintains lead over rival Singapore in key financial metrics.

8 Jul 2025 - 9:07PM

(From left): Olga Wong, deputy Hong Kong editor, South China Morning Post; Benny Miao, executive vice president, Cathay United Bank; Eden Woon, president, American Chamber of Commerce in Hong Kong; and Dato’ Seri Cheah Cheng Hye, honorary chairman and non-executive director, Value Partners Group, attend the China Conference 2025. Photo: Eugene Lee

Biomedicine: Companies

Hong Kong’s Phase Scientific gets US$34 million to advance test for HPV

Company says its test is the world’s first urine-based screening for the virus that causes 95 per cent of cervical cancer cases.

20 May 2025 - 9:00AM

China stock market

Global fund managers get key China licences as country opens up

10 Nov 2017 - 5:56PM

The Insider

The Insider | Insider activity quiet ahead of Lunar New Year, funds active

29 Jan 2017 - 7:39PM

Insider activity quiet ahead of Lunar New Year, funds take the spotlight

Value Partners profit slumps 96pc

Net income fell to HK$3.3 million for the six months to June, in line with the company's profit warning in July. That was the lowest six-month profit for the firm since the depths of the global financial crisis in the second half of 2008.

14 Aug 2013 - 1:51AM

HK fund firm joins mainland venture

9 Mar 2012 - 12:00AM

career tracker

23 Jul 2011 - 12:00AM

Small stocks, big ideas drive Value Partners boss

24 Dec 2007 - 12:00AM

Value Partners to offload shares in HK$2.9b listing

8 Nov 2007 - 12:00AM

Value Partners upbeat on mainland prospects

5 Nov 2007 - 12:00AM

Corrections & clarifications

19 Jun 2004 - 12:00AM

SFC raps dealer for year-end buy trade

6 Oct 2000 - 12:00AM

Investor seeks out the engines for mainland's through train

15 Aug 1999 - 12:00AM

US firm takes stake in Value

7 Jul 1998 - 12:00AM

Help preserve 120 years of quality journalism.

SUPPORT NOW

Value Partners

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

China’s resources deals turn gold mines into – gold mines

China’s divergent stock market displays a microcosm of the nation’s economy

The stock market catalogues China’s uneven growth, as manufacturing expands and consumption falls.

Is Hong Kong losing its tech edge to the mainland’s AI boom?

Chinese investors are shifting from Hong Kong to mainland stocks, driven by AI opportunities and better returns.

China equities set for boost as Trump-Xi meeting raises hopes of thaw

Investors are betting a Trump-Xi summit will ease tensions, helping Chinese equities close their long-standing valuation gap.

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Trump’s Fed pick Warsh stokes uncertainty as investors weigh his policy shifts

US Treasuries have been falling recently, partially reflecting investor concerns that Warsh’s succession will slow rate reductions.

Hong Kong’s new cash-for-residency scheme draws US$12 billion in first 2 years

Number of applicants surges in second year, with most of the deployed capital going into authorised funds, equities and debt securities.

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

.css-1f6sr3w{color:#727272;}Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Hong Kong taps Value Partners, 9 others to manage US$385 million residency fund

Government investment arm HKIC also names Primavera among managers of CIES IP, which focuses on Hong Kong’s long-term development.

Adams Street joins wave of investment firms opening in Hong Kong

‘We want to be closer to both our investors and the investment opportunities that are presenting themselves here,’ managing partner says.

JD’s property arm joins 2 firms in US$1 billion Singapore Reit: sources

JD Property is setting up the US$1 billion Reit with Swiss investment firm Partners Group and Hillhouse’s EZA Hill Property, sources said.

Efforts needed to combat view ‘Hong Kong equals mainland China’: business leaders

Panellists at South China Morning Post’s China Conference 2025 also say city maintains lead over rival Singapore in key financial metrics.

Hong Kong’s Phase Scientific gets US$34 million to advance test for HPV

Company says its test is the world’s first urine-based screening for the virus that causes 95 per cent of cervical cancer cases.

Global fund managers get key China licences as country opens up

.css-1pcrwvc{color:#2aa191;}The Insider | Insider activity quiet ahead of Lunar New Year, funds active

Value Partners profit slumps 96pc

Net income fell to HK$3.3 million for the six months to June, in line with the company's profit warning in July. That was the lowest six-month profit for the firm since the depths of the global financial crisis in the second half of 2008.

HK fund firm joins mainland venture

career tracker

Small stocks, big ideas drive Value Partners boss

Value Partners to offload shares in HK$2.9b listing

Value Partners upbeat on mainland prospects

Corrections & clarifications

SFC raps dealer for year-end buy trade

Investor seeks out the engines for mainland's through train

US firm takes stake in Value

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

The Insider | Insider activity quiet ahead of Lunar New Year, funds active